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Oxygen is an essential regulator of cellular metabolism, survival, and proliferation. Cellular responses to oxygen levels are monitored,
in part, by the transcriptional activity of the hypoxia inducible factors (HIFs). Under hypoxia, HIFs regulate a variety of pro-angiogenic
and pro-glycolysis pathways. In solid cancers, regions of hypoxia are commonly present throughout the tissue because of the chaotic
vascular architecture and regions of necrosis. In these regions, the hypoxic state fluctuates in a spatial and temporal manner. Transient
hypoxic cycling causes an increase in the activity of the HIF proteins above what is typical for non-pathologic tissue. The extent of
hypoxia strongly correlates to poor patient survival, therapeutic resistance and an aggressive tumour phenotype, but the full
contribution of hypoxia and the HIFs to tumour biology is an area of active investigation. Recent reports link resistance to
conventional therapies and the metastatic potential to a stem-like tumour population, termed cancer stem cells (CSCs). We and
others have shown that within brain tumours CSCs reside in two niches, a perivascular location and the surrounding necrotic tissue.
Restricted oxygen conditions increase the CSC fraction and promote acquisition of a stem-like state. Cancer stem cells are critically
dependant on the HIFs for survival, self-renewal, and tumour growth. These observations and those from normal stem cell biology
provide a new mechanistic explanation for the contribution of hypoxia to malignancy. Further, the presence of hypoxia in tumours
may present challenges for therapy because of the promotion of CSC phenotypes even upon successful killing of CSCs. The current
experimental evidence suggests that CSCs are plastic cell states governed by microenvironmental conditions, such as hypoxia, that
may be critical for the development of new therapies targeted to disrupt the microenvironment.
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Oxygen concentration is tightly regulated at the tissue and cellular
levels because of its essential role in many biological processes.
Hyperoxia can induce the formation of reactive oxygen species
(ROS), which may cause genotoxic effects or cell death. In contrast,
hypoxia can have extensive downstream transcriptional effects,
such as activation of pro-apoptotic and pro-angiogenic pathways.
Nonpathological cells have regulatory mechanisms to quickly
respond to variations in oxygen tension by the hypoxia inducible
factors (HIFs). Neoplastic cells employ oxygen-sensitive activity
of the HIF proteins. The HIFs also have higher basal activity in the
neoplastic compartment. However, this enhanced level of tran-
scriptional activity is not fully understood. It can be partly
attributed to the state of oxygenation within a tumour, which is not
consistent and behaves in a cyclical nature. The flux in oxygen
tension experienced by cancer cells is an effect of several tumour
characteristics such as chaotic vasculature, poor oxygen diffusion
across an ever-expanding tumour, and irregular blood flow.
Several studies have shown that the constant acute cycling of
hypoxic regions in a tumour leads to enhanced metastatic potential
and HIF transcriptional activity beyond what is typical of healthy
tissue (Cairns et al, 2001; Peng et al, 2006). Oxygenation status
of tumour tissue cycles in both spatial and temporal manner.
Studies in mice utilising window chamber imaging techniques
demonstrated that hypoxic cycling occurs often in regions of
microvasculature because of the instability of red blood cell flow
through the vessels (Kimura et al, 1996). Consequently, this
regional cycling results in fluctuating HIF activity, which has been
shown to directly correlate to tumour radiation resistance (Moeller
et al, 2004; Dewhirst et al, 2008). Recent experimental evidence has
expanded on the role of hypoxia in cancer by demonstrating
differential responses to hypoxia between heterogenic sub-
populations within the tumour. One of these populations, termed
cancer stem cells (CSCs), possess many phenotypic similarities to
normal stem cells, such as having the ability to upregulate DNA
repair kinases to evade radiation-induced genomic damage (Bao
et al, 2006a). Although somewhat controversial, hypoxia has
become increasingly related to the cancer stem cell phenotype. The
role of HIFs in these cells has become an important focus in
understanding tumour growth and survival (Hill et al, 2009).
STEM-LIKE CELLS IN SOLID TUMOURS
Virchow proposed the embryonic rest theory in cancer (Virchow,
1858) 150 years ago. In the early twentieth century several
connections were made between cancer cells and less-differen-
tiated normal cells. In a seminal work, the Dick laboratory isolated
patient-derived stem-like leukaemia cells that were capable of
initiating de novo leukaemia in SCID mice (Lapidot et al, 1994).
They also demonstrated that myeloid leukaemia cells were
organised as a hierarchy and originated from a primitive
haematopoietic cell (Bonnet and Dick, 1997). Dick’s studies in
leukaemia were furthered by Clarke and colleagues (Al-Hajj et al,
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cancer. They discovered a subset of cells that could be
prospectively enriched in their cultures by fluorescence-activated
cell sorting (FACS) for surface markers typically associated with
normal stem cells, CD44 and CD24 (Al-Hajj et al, 2003). The cells
that expressed this marker pattern were shown to be more
tumourigenic in SCID mice. In addition, tumours arising from this
sub-population maintained the phenotypic heterogeneity present
in the primary tumour, suggesting that the stem-like sub-
population within breast cancer was primarily responsible for
the formation of tumour and establishment of neoplastic hetero-
geneity. These cells, known as cancer stem cells, tumour initiating
cells, or tumour propagating cells, utilise many unique survival
techniques to propagate the tumour, some of which are similar to
those found in normal somatic stem cells. Since this early work,
several groups have demonstrated the presence of cancer stem cells
in other solid tumours, including malignant glioma and colorectal
cancer (Singh et al, 2003; Ricci-Vitiani et al, 2007).
Cancer stem cells contribute to tumour growth, maintainence,
and recurrence after therapy through multiple mechanisms and
networks. One important characteristic of these cells is their ability
to restrict DNA damage sustained during radiation or chemo-
therapy by reduction of ROS and enhanced activity of DNA
checkpoint kinases (Bao et al, 2006a; Diehn et al, 2009). By
preventing DNA damage, the cancer stem cell population survives
injury and can continue to propagate the tumour. CSC were also
shown to be dependant on the Akt signalling pathways, as the
cancer stem cell sub-population had increased sensitivity to
chemical Akt inhibitors (Eyler et al, 2008). To enrich in vitro
cultures for this population, sorting protocols were developed that
took advantage of unique markers expressed by cancer stem cells
when compared with the bulk of the tumour (Figure 1). Additional
experimental evidence has demonstrated that one of the important
roles the cancer stem cell population has in a tumour is in
regulating tumour angiogenesis by vascular endothelial growth
factor (VEGF) signalling.
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Figure 1 Enrichment of cultures for cancer stem cells allow for better study of their unique biology. In order to appropriately examine the biological
significance of the cancer stem cell population, in vitro cultures must be enriched for this population before experimental investigation. Utilising animal
models, such as immunocompromised mice, patient-derived cancer cells can be expanded for use in the laboratory. Following resection of the tumour from
the patient, the mass is dissociated into single cells through a combination of mechanical and enzymatic digestion. Once the cells have recovered and are
growing as single cells, they can be sorted based on surface marker expression. Experimental evidence has demonstrated that the cancer stem cell sub-
population express a subset of genes that can act as markers for enriching cultures for the stem-like cancer cells (Singh et al, 2003). The present gold
standard of these markers in glioma is the surface protein, CD133 (also known as Prominin-1). CD133 can be used in cell sorting to discern the cancer stem
cell sub-population. Although little is known about its role in cancer biology, (A) CD133 expression has been observed on a sub-population of cells in the
tumour tissue and (B) this expression is maintained in the cancer stem cell population in vitro.I n( A) a subcutaneous tumour was resected out of a mouse,
fixed in paraformaldehyde, and frozen. Sections of the tumour were cut and stained for CD133 (red) and nuclei (Hoescht 3342, blue). In (B) cancer stem
cells enriched from glioblastoma multiforme were cultured in serum-free media until they formed spheroids (neurospheres). The cells were then fixed,
frozen, and cut. The sections were stained for CD133 (green) and nuclei (Hoescht 3342, blue). This procedure allowed for direct staining of cells throughout
the sphere. Once the tumour cells have been separated into cancer stem cell (CSC)-enriched and non-CSC populations, experiments can be carried out to
elucidate the biological differences between the two populations. The most important way to test CSC biology is the ability of the cancer stem cells to form
tumours that are phenotypic copies of the parental tumour. In the glioma system, one way to determine a cells tumourigenic capacity is direct intracranial
implantation. In this way, the tumour formation capacity of cancer cells allows researchers to delineate the stem-like fraction of cells within a tumour.
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canonical downstream effect of HIF transcriptional activity. As
cells grow and divide, the neoplastic compartment rapidly expands
past the diffusion distance of oxygen in tissue (B100mm). Large
regions of the tumour become hypoxic because of this spatial
limitation. The immediate cellular response (mediated by HIF
proteins) is the influx of new vessels to provide appropriate
oxygenation to the tumour tissue. However, vessel ingrowth
cannot maintain proper tissue oxygenation when faced with the
rapid cellular expansion of a tumour. This constant imbalance
between cell and vessel growth causes a fluctuating oxygen state.
These transient states of hypoxia are a common characteristic of
solid tumours. Although normal oxygen tension in healthy tissue
is approximately 7% oxygen (53mmHg), this tension in a tumour
can range from physiological (B7%) to severe (o1%) oxygen.
Severe hypoxia is less frequent but commonly found surrounding
areas of necrosis, which is another common characteristic of solid
tumours. The immediate molecular response to low oxygen is
stabilisation of the HIF proteins. Hypoxia inducible factors
stimulate the expansion and migration of endothelial cells into
the tumour space, which allow new vessel growth from the existing
vasculature structure surrounding the tumour. The formation of
these vessels supplies the rapidly expanding tumour with nutrients
and oxygen. However, the vasculature is very chaotic and does not
transfer nutrients and oxygen efficiently (Baish and Jain, 1998).
This is thought to be a consequence of the number of angiogenic
signals coming from the neoplastic cell population, such as VEGF
and the angiopoietins. However, until recently it was hypothesised
that the majority of cells in the tumour were capable of regulating
this angiogenic signal. It is now known that there is heterogenic
expression of VEGF within a tumour. The cancer stem cell sub-
population has been shown to be the primary regulator of
angiogenesis in a tumour by the production of VEGF (Bao et al,
2006b). The chaotic vessel formation is another factor in the
constant oxygen flux observed in solid tumours (Carmeliet and
Jain, 2000). High frequency of cycling (acute) hypoxia correlates
to lower patient survival. This sensitivity of tumour structure to
oxygen status is driven by the HIF proteins in the cancer stem cell
population.
OXYGEN SENSITIVE HIF ACTIVITY
The HIFs are transcription factors whose expression and stability
is regulated by oxygen tension. They exist as a heterodimer,
consisting of an alpha and beta subunit. There are three isoforms
of the alpha subunit: HIF1a, HIF2a (also known as endothelial
PAS-domain protein 1, EPAS1), and HIF3a. The HIFb isoforms,
also known as aryl hydrocarbon receptor nuclear translocator
(ARNT and ARNT2), are constitutively and ubiquitously expressed
across many cell types (Maltepe et al, 1997; Keith et al, 2001).
The present understanding of HIF regulation has described the
majority of oxygen-controlled HIF regulation occurring on the
alpha subunit, whereas the beta subunit is not sensitive to oxygen
levels and is constitutively present in the nucleus. The HIF1a
subunit is a basic helix-loop-helix protein whose structure and
function is evolutionarily conserved between mice and humans
(Iyer et al, 1998). Hypoxia inducible factor-1a has been well-
studied and is ubiquitously expressed in normal tissue. Further
studies characterized a second HIFa isoform as also being tightly
regulated by oxygen tension. Since its initial discovery, HIF2a was
demonstrated to have shared transcriptional targets with HIF1a
such as VEGF, Tie-2, Ang2, and Flt1 (VEGF-R1). HIF1a and HIF2a
also bind homologous target DNA-binding sequences (Lau et al,
2007). Despite their similarities, HIF2a expression was restricted to
endothelial cells of vascular organs and had several unique
transcriptional targets such as Oct4 and TGFa. These targets are
outside the canonical pro-angiogenic hypoxic response, which
suggests an important and specific role for HIF2a in regulating
other cellular processes such as pluripotency. Little is known about
the third HIFa isoform. Several splice variants of HIF3a have been
shown to be a dominant-negative regulator of the other two alpha
isoforms and has a limited expression pattern in the eye and the
cerebellum. Some HIF3a isoforms are also thought to be direct
transcriptional targets of HIF1a activity under hypoxia. Current
studies are still unclear as to the primary function and regulatory
mechanism through which HIF3a and its variants function
(Makino et al, 2001; Maynard et al, 2003).
Certain disease states allow for the stabilisation of the HIFa
subunit even in the presence of oxygen. One of the more well-
known conditions is renal cell carcinoma (RCC). In RCC, there is
a biallelic inactivation of the E3 ubiquitin ligase responsible for
targeting the HIFa subunits for degradation. Renal cell carcinoma
patient specimens have higher activity of HIF regulated pathways
such as increased angiogenesis, altered glucose uptake and
metabolism, and loss of growth control by mitogenic signals.
HIF1a and HIF2a have unequal roles in RCC and HIF2a is more
important for disease progression. Inhibition of HIF2a suppresses
in vivo tumour growth (Kondo et al, 2003). This suggests that in a
system where both HIF1a and HIF2a are stabilized and functional,
HIF2a is critical to tumour growth and survival whereas HIF1a is
not. HIF2a is stabilized at a wider range of oxygen tensions,
ranging from severe hypoxia (o1% oxygen) to more physiologi-
cally relevant tension for tumours (2–5% oxygen) (Holmquist-
Mengelbier et al, 2006). HIF2a can respond to a wider range of
oxygen tensions to activate downstream transcriptional targets.
The tumour would have the capability to adapt to an ever-
changing microenvironment beyond the regions of most severe
hypoxia. However, HIF1a also has a role in addition to HIF2a in
promoting tumour growth. In solid tumours HIF1a has been
linked to regulating oncogene activity through AKT and epidermal
growth factor receptor (EGFR) pathways. The different roles and
expression patterns of HIF1a and HIF2a demonstrate that their
specificity is important for tumour propagation and survival. The
HIFs have been demonstrated to be expressed in the cancer stem
cell population, possibly promoting the stem-like phenotype and
driving tumour growth.
The role of HIFs in cancer stem cells
Although originally described in endothelial cells as regulators of
migration and erythropoiesis, the HIF proteins have since been
implicated in many cell processes. Specifically in cancer, they are
critical for the ingrowth of vasculature to feed the rapidly
expanding neoplastic compartment. As more is understood about
the methods of tumour propagation, hypoxia has become a critical
microenvironmental influence. Lending support to this theory is
the recent evidence linking HIF expression in cancer stem cells
to cell proliferation and tumour survival.
Early work on HIFs and cancer focused on HIF1a and
demonstrated that the majority of tumour cells responded to
hypoxia by stabilizing the HIF1a protein. In many cases HIF2a
expression was not found or was no different between hypoxia
and normoxia. The conclusion was drawn that HIF1a, not HIF2a,
was responsible for the majority of the hypoxia response in cancer.
However, recent experimental evidence from our laboratory has
demonstrated differential protein and mRNA expression of HIF1a
and HIF2a between the non-stem and cancer stem cell (Li et al,
2009). Further, this study elucidated that HIF2a was only
significantly present in the cancer stem cell population. In
comparison, HIF1a was present in both stem and non-stem
tumour cell population and was only stabilized in more severe
hypoxic conditions. This finding suggests differential roles of the
two isoforms in cancer stem cells. Furthermore, several genes
previously associated with the hypoxic response in normal cells
were shown to have higher expression in the cancer stem cell
HIFs in cancer stem cells
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2006b; Li et al, 2009). Following in vivo knockdown experiments,
this study concluded that HIFs were required for cancer stem
cell survival and tumour propagation. Cancer stem cells that
had diminished HIF activity were unable to form tumours and
had reduced survival in vitro. This suggests that HIFs has a much
larger role in cancer stem cells than initially hypothesised.
Current studies are demonstrating an increased importance of
the HIF proteins in maintaining an undifferentiated phenotype
(Jogi et al, 2002).
HIFs promote a stem cell phenotype
Several reports have shown that hypoxia and HIFs are involved in
maintaining a more stem-like state in normal tissue (Clarke and
van der Kooy, 2009; Moreno-Manzano et al, 2009). Through
signalling pathways like Notch and Oct4, the HIFs are being
understood as crucial regulators of the stem cell phenotype
(Gustafsson et al, 2005). Recent reports have demonstrated
the ability of the hypoxic microenvironment to greatly potentiate
the biological effect of Notch in adenocarcinoma of the lung (Chen
et al, 2007). In tissues throughout the body, stem cells persist in
specific anatomical locations, also referred to as niches. One
example of these niches can be found in bone marrow where
haematopoietic stem cell are known to reside in regions regulated
by oxygen tension (Parmar et al, 2007). Growing evidence supports
the hypothesis that stem cells residing in hypoxic niches rely on
HIF activity to maintain their undifferentiated phenotype. It is
interesting to note that the presence of hypoxic areas within a
tumour also suggest possible niches for cancer stem cells
(Gilbertson and Rich, 2007). The correlation of tumour hypoxia
to poor patient outcome may be related to an increase in the
presence of cancer stem cells. In the emerging field of induced
pluripotency, a recent study by Yamanaka and colleagues (Yoshida
et al, 2009) has shown that culture in hypoxia significantly
improves the generation of iPS colonies following reprogramming.
Current understanding of cancer stem cell biology and their
similarities to somatic stem cells suggest that hypoxia and the HIFs
may act to regulate the cancer stem cell phenotype.
Increasing experimental evidence suggests that hypoxia and the
HIFs regulate the sub-population of cancer stem cells. A recent
study demonstrated that culture in hypoxia and activation of
HIF1a expands the sub-population of cells positive for cancer stem
cell marker, CD133 (Soeda et al, 2009). Cells under hypoxia
also increased other markers associated with a more stem-like
phenotype, such as CD44. At the same time, markers of neuron
lineages (b3 Tubulin and GFAP) decreased in these cells. A study
from Pahlman and colleagues (Jogi et al, 2002) has also shown that
hypoxia in neuroblastoma cells can alter gene expression to that of
a more immature phenotype. These data suggest that the fraction
of a tumour considered to be cancer stem cells is plastic depending
upon microenvironmental signals such as hypoxia. It is further
hypothesised that the cancer stem cell phenotype may be a cell
state induced in cancer cells depending on external and internal
signals (Figure 2). The plasticity of the cancer stem cell state could
have far reaching implications in how treatment of solid tumours
is approached. Several groups have recently published data
demonstrating this critical, and previously unknown, role of
hypoxia in maintaining the stem-like fraction of cancer cells (Jogi
et al, 2002; Heddleston et al, 2009; McCord et al, 2009).
McCord et al (2009) showed that hypoxia not only increased
the fraction of CD133-positive cells, but also enhanced the stem-
like phenotype of cell lines. By evaluating in vitro measures of the
cancer stem cell phenotype, such as tumoursphere formation and
stem cell marker expression, they showed that the stem-like
population was enhanced. Using microarray techniques, they also
determined that other genes related to stem cell functions, Sox2
and Oct4, were also increased in cells under hypoxia. It is
interesting to note that these data showed genetic changes
occurring at 7% oxygen where only HIF2a is known to be
stabilized. This suggests a specific role of HIF2a in the plasticity of
phenotype in cancer cells. Pahlman and colleagues (Pietras et al,
2008) demonstrated that expression of HIF2a, specifically, denotes
neuroblastoma and breast cancer cells with a more immature
phenotype and the presence of HIF2a-positive cells correlates to
poor patient outcome. Data from the National Cancer Institute’s
REMBRANDT database supports the findings of McCord and
Pahlman, in which patients with higher expression of HIF2a
Non-stem cancer cells
Proliferation
EdU Hoescht
Self-renewal
Hypoxia
Tumourigenicity
Figure 2 Hypoxia and the hypoxia inducible factors (HIFs) can promote the stem-like phenotype. Recent experimental evidence has demonstrated that
HIFs have crucial roles in cancer. Following culture in low-oxygen conditions, the phenotype non-stem cancer cells were pushed to a more stem-like state.
Several important characteristics of the cancer stem cell population, such as enhanced growth, self renewal (evidenced by spheroid formation), and
tumourigenesis, have been shown to increase in the non-stem fraction of cancer cells following hypoxic culture (Heddleston et al, 2009). Non-stem cells
increase their rate of proliferation above what is normally seen at 20% oxygen. This can be visualised by EdU retention (an analogue of BrDU). Hypoxia has
also been shown to promote self-renewal, which can be measured by spheroid growth starting from a single cell. Non-stem cancer cells expressing
constitutively active HIF2a protein have been demonstrated to have increased tumourigenicity in mice animal models.
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of the National Cancer Institute, accessed 2 September 2009).
Recently, it has been demonstrated that hypoxia is responsible
for altering cellular phenotype by increasing proliferation,
self-renewal, and the upregulation of stem genes in both stem
and non-stem cancer cell populations (Figure 2A). Specifically, the
HIF2a component of the hypoxic response can increase the
expression of stem cell-associated genes and confer tumourigenic
potential to non-stem cells (Heddleston et al, 2009). HIF2a
transcriptionally regulates Oct4 (Covello et al, 2006). In addition,
Oct4 and Nanog are part of the unique genetic signature of cancer
cells (Ben-Porath et al, 2008; Ji et al, 2009). Together these
studies outline a more sophisticated function of HIF2a outside
of the canonical hypoxic responses. By regulating pathways
associated with normal stem cell pluripotency, HIF2a may alter
basic genetic activity of cancer cells to a more stem-like phenotype
depending on the constantly fluctuating state of oxygen in the
tumour. These findings are significant in showing that not only
is HIF2a a critical part of the hypoxic response in cancer stem
cells, but that it can promote a more stem-like phenotype in stem
and non-stem cancer cells.
DISCUSSION
Tumour cell heterogeneity is currently modelled in two paradigms:
stochastic and hierarchical models. The stochastic model posits
that most cells within a tumour possess the ability to self-renew to
maintain phenotypic copies of themselves. In addition, many
phenotypically distinct cell populations in the tumour are able
to recapitulate the primary tumour in a secondary location.
The hierarchical model suggests that cells within a tumour are
organised in a hierarchy, similar to normal stem cells. At the top
of the hierarchy are cancer stem cells, which are the only cells that
are able to self-renew and propagate the tumour. The other cells in
the hierarchy are phenotypically distinct from the cancer stem cell
and do not possess stem-like characteristics. However, these
present models do not completely fit what is known about cancer
stem cell biology, especially with the recent demonstration of
HIF2a promoting a more stem-like phenotype in cancer cells.
In order to better understand tumour biology, new approaches
to how cancer cells form the tumour are needed.
The cells that comprise a tumour can instead be modelled as
accumulation of mutations or alterations in epigenetic regulation
(Figure 3). In the first proposed model, as cancer cells grow and
divide they acquire new mutations, which give them distinct
growth and survival advantages over previous generations. This
can be observed in secondary tumours. Tumours that recur
following treatment and resection (secondary tumousrs) are
typically more resistant to further treatment and have a more
aggressive phenotype. The increase in aggressive phenotype could
be because of the cancer cells that acquired enough genetic
mutation to survive treatments. However, the other aspect to this
model is the genetic changes that occur are irreversible and do not
allow for phenotype plasticity in the cancer cell population.
A different way tumour biology could be modelled is by alterations
in epigenetic regulation. Cells considered to be ‘cancer stem cells’
may have a less restricted epigenetic structure, such as loss of
Histone 3 methylation, and not contain any new genetic mutations
compared with the rest of the tumour. The lower genetic
restriction allows the cell access to a wider variety of genetic
transcripts and survive injury that may be sustained following
patient treatment. As cells become more repressed by epigenetic
silencing (DNA and histone methylation), they can become more
differentiated and exhibit less stem-like behaviours. It is important
to note that this model of tumour biology does not exclude the
possibility of plasticity in the cellular phenotype. Recent experi-
mental evidence supports the theory that ‘stemness’ may be
regulated by the microenvironment. Several groups have shown
that hypoxia can regulate the activity of histone demethylases
(Xia et al, 2009). Differential histone methylation is known to be
characteristic of embryonic stem cells and this suggests that
hypoxia may effect the cancer cell phenotype by altering the
epigenetic structure (Pan et al, 2007). The implications of this
Accumulation of mutation
= Cancer stem cell
Epigenetic alterations
Mutation
Tumour
Tumour
Hypoxia
HIF2α
Figure 3 A new paradigm in modelling tumour biology. Classically cancer cell biology has been modelled in a stochastic or hierarchical sense. These
models focus on which cells within a tumour population are responsible for tumourigenicity, but treat cellular progression an irreversible process: either all
(or a large majority) can form tumours even as the cell phenotype may change, or that only the parental cells of the hierarchy (cancer stem cells) can form
tumours, whereas their differentiated progeny act as a support structure. A new way to view the cellular organisation of tumour is to focus on how a cell
may acquire the ability to be tumourigenic, rather than what definitive cell population forms the tumour. The mutation model posits that the ability to form
tumours is because of an accumulation of specific mutations that allow the cells to evade therapy and growth more rapidly. In this model, each mutation is
irreversible and the accumulation of important mutations (e.g. p53, EGFR) allows for a sustained sub-population of cancer stem cells. The second model
describes the cellular structure of the tumour to be more plastic and allow for cellular adaptation to the microenvironment. The cancer stem cell sub-
population drives tumour growth, but this population arises from adaptation of the cells to their microenvironment. External influences, such as hypoxia, can
drive a reversible phenotype that can enhance stem-like properties of cells to ensure survival of the tumour.
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that hypoxia is an under-studied and under-appreciated factor in
regulating cell fate.
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